autoimmunity

STAT5 Protein Complex Implicated in MS Autoimmunity in Mice

A four-protein complex, or tetramer, of the protein STAT5 is involved in the development of multiple sclerosis (MS)-like autoimmune disease in mice, a new study shows. The findings point to this protein complex and its signaling pathway as a potential treatment in MS and other autoimmune conditions, scientists noted.

Study Finds Lemtrada Safe for MS Patients With Other Autoimmunity

Other autoimmune conditions, particularly those characterized by the presence of anti-TPO antibodies, should not preclude patients with multiple sclerosis (MS) from receiving treatment with Lemtrada (alemtuzumab), according to an analysis of pooled data from clinical trials and post-market data. The study, ā€œAutoimmunity and long-term safety and efficacy…

Nimbus, Celgene to Jointly Research Targeting of Proteins to Treat MS, Other Disorders

Nimbus Therapeutics and CelgeneĀ have agreed to work together to identify potential therapeutic compounds that can specifically target Tyk2 and STING ā€” two proteins involved in inflammation and innate immune response. This strategic collaboration can open new therapeutic avenues for the treatment of multiple sclerosis (MS) and several autoimmune disorders. Nimbus, headquartered in Cambridge, Massachusetts, applies chemical computational analysis to identify and develop new compounds with potential for therapeutic use in a range of diseases. TwoĀ Nimbus immunology programs are already covered under the newly established agreement: one developing inhibitors of Tyk2 and antagonists of STING protein. Tyk2, or tyrosine kinase 2, mediates the signaling of several pro-inflammatory proteins, including interleukin (IL)-23, IL-12 and type-I interferons. Inhibiting this enzyme can stop signals from passing through. This can potentially impair inflammatory response. STING, or stimulator of interferon genes, is an important activator of immune responses. As such, finding ways to block its activity can help prevent autoimmunity and reestablish immune response balance. Under their accord, Nimbus will control the program's research and development; Celgene will have the option to acquire each program covered by the alliance.

Autoimmunity Traced to Failure of B-cell Protein, Caveolin-1, to Work as Intended in Study

A newĀ and potentially important mechanism in the development ofĀ autoimmune diseases likeĀ multiple sclerosis was discovered by scientists at the University of Freiburg, Germany. They identify aĀ protein, called Caveolin-1, that is essential to immune cells called B-cells working as intended to protect a person from pathogens or ā€” in its absence…

Mode of Action for MS Drug Showing Promise in Phase 3 Clinical Trials Uncovered

In a new study, researchers at theĀ Scripps Research Institute (TSRI)Ā uncovered the molecular mechanisms behind the perceived clinicalĀ efficacyĀ of a specific drug type, sphingosine 1-phosphate receptor 1 (S1PR1) agonists, toĀ diminish the harmful immune response that leads to autoimmunity in multiple sclerosis (MS) and other diseases, while still preserving the immune system’s…

MS Patients on Salt-heavy Diets Risk Inflammation

Findings from two studies, recently published in theĀ Journal of Clinical Investigation, indicate that high levels of salt alter the stability of the immune system and make it more susceptible to inflammation. The studies, which were led by Dr. David Hafler from Yale University and Dr. Dominik…